## CPTC-EGFR-9 (CAB080315)

#### Uniprot ID: P00533

Protein name: EGFR\_HUMAN

Full name: Epidermal growth factor receptor

Tissue specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Function: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascade including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Isoform 2 may act as an antagonist of EGF action. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

Subcellular location:

#### Unnamed:

Cell membrane (experimental evidence) (Topo: Single-pass type I membrane protein (experimental evidence))

Endoplasmic reticulum membrane (experimental evidence) (Topo: Single-pass type I membrane protein)

Golgi apparatus membrane (Topo: Single-pass type I membrane protein)

Nucleus membrane (Topo: Single-pass type I membrane protein)

Endosome (experimental evidence)

Endosome membrane

Nucleus (experimental evidence)


NOTE: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546, PubMed:17909029). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536, PubMed:17909029). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055).

Isoform 2: Secreted

Protein existence: Experimental evidence at protein level


Comment:

### Immunohistochemistry



| IHC protocol:            | HIER pH6, Dilution 1:400   |  |
|--------------------------|--|--|
| IHC test staining:       | No positivity was observed.  |  |
| Literature conformance:  | Not consistent with gene/protein characterization data                 |  |
| Literature significance: |  |  |
| RNA similarity:          | Very low consistency between antibody staining and RNA expression data |  |
| RNA tissue specificity:  | Low tissue specificity   |  |
| RNA tissue distribution: | Detected in many   |  |
| IHC Sibling similarity:  | Other antibody shows dissimilar IHC staining pattern                   |  |

### Immunofluorescence



| IF Overlay:                         | antibody (green), anti-tubulin (red) and DAPI (blue) |
|-------------------------------------|--|
| IF main location:                   |  |
| IF additional location:             |  |
| IF approved for publication on HPA: | No   |
| IF in THP-1:                        | Negative   |
| IF in U2OS:                         | Negative   |

# Western blot

| -   | WB Size markers (kDa):  | 250, 130, 100, 70, 55, 35, 25, 15, 10  |
|---|-------------------------|--|
|   | WB Lanes:               | Marker (1), RT-4 (2), U-251MG (3), Plasma (4), Liver (5), Tonsil (6)   |
|   | WB Target weight (kDa): | 15, 45, 69, 77, 121, 129, 134  |
| -   | WB Validation:          | Uncertain (Single band larger than predicted size in kDa (+20%) but partly supported by experimental and/or bioinformatic data.) |
|   |                         |  |
|   |                         |  |
| wine and the second  |                         |  |
|   |                         |  |
|   |                         |  |
| and the second se |                         |  |
|   |                         |  |
|   |                         |  |
|   |                         |  |
|   |                         |  |